Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
13 juin 2024 07h00 HE
|
Matinas BioPharma Holdings, Inc.
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids
12 janv. 2023 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
02 nov. 2022 16h02 HE
|
Matinas BioPharma Holdings, Inc.
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment...
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
21 oct. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022
12 oct. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial Late-breaking data demonstrate that...
BioNTech und Matinas BioPharma geben exklusive Forschungskollaboration zur Entwicklung neuer Formulierungen für mRNA-basierte Impfstoffe bekannt
11 avr. 2022 07h00 HE
|
BioNTech SE
Exklusive Forschungskollaboration kombiniert BioNTech’s Expertise in der Entwicklung mRNA-basierter Impfstoffe mit Matinas Lipid-Nanokristall (LNC)-Plattformtechnologie zur Entwicklung...
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
11 avr. 2022 07h00 HE
|
BioNTech SE
Exclusive collaboration combines BioNTech’s mRNA vaccine development expertise and Matinas’ Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines,...